NYSTATIN- nystatin suspension
Taro Pharmaceuticals U.S.A., Inc.

Nystatin
Oral Suspension,
USP

Rx Only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Structural formula:



Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤1% v/v), benzaldehyde, edetate calcium disodium, flavors, glycerin, magnesium aluminum silicate, methylparaben, propylparaben, purified water, saccharin sodium, sodium citrate, sucrose (49.8% w/v), xanthan gum.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by

binding to sterols in the cell membrane of susceptible *Candida*species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

See **DOSAGE AND ADMINISTRATION**.

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

*Gastrointestinal:*Diarrhea (including one case of bloody diarrhea), nausea, vomiting,

gastrointestinal upset/disturbances.

*Dermatologic:*Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:*Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

INFANTS

2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS

4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

HOW SUPPLIED

Nystatin Oral Suspension, USP, 100,000 USP Nystatin U/mL, is available as a cherry-mint flavored, light creamy yellow, ready-to-use suspension in:

2 fl oz (60 mL) bottles with 0.5 mL, 1 mL, 1.5 mL, 2 mL calibrated dropper NDC 51672-4117-4 1 Pint (473 mL) bottles NDC 51672-4117-9 1 Gallon (3785 mL) bottles (For repackaging only) NDC 51672-4117-0

SHAKE WELL BEFORE USING

Storage

Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Protect from freezing.

PHARMACIST: Dispense in a tight, light-resistant container as defined in USP.

Manufactured by:
Taro Pharmaceutical Industries Ltd.
Haifa Bay, Israel 2624761

Distributed by:
Taro Pharmaceuticals U.S.A., Inc.
Hawthorne, N.Y. 10532

Revised: May 2019
70564-0519-2

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label

NDC 51672-4117-4

2 fl oz
(60 mL)

Nystatin

Oral Suspension USP,

100,000 units/mL

SHAKE WELL BEFORE USING

CHERRY/MINT FLAVORED

TARO

Rx only



NYSTATIN
nystatin suspension

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:51672-4117
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 [USP'U] in 1 mL

Inactive Ingredients

Ingredient Name	Strength
ALCOHOL (UNII: 3K9958V90M)	
BENZALDEHYDE (UNII: TA269SD04T)	
EDETATE CALCIUM DISODIUM (UNII: 25IH6R4SGF)	
GLYCERIN (UNII: PDC6A3C0OX)	
MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
SACCHARIN SODIUM (UNII: SB8ZUX40TY)	
SODIUM CITRATE, UNSPECIFIED FORM (UNII: 1Q73Q2JULR)	
SUCROSE (UNII: C151H8M554)	
XANTHAN GUM (UNII: TTV12P4NEE)	

Product Characteristics

Color	yellow (light creamy yellow)	**Score**	
Shape		**Size**	
Flavor	CHERRY (Cherry-mint flavored)	**Imprint Code**	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:51672-4117-4	1 in 1 CARTON	02/29/1988	
1		60 mL in 1 BOTTLE, DROPPER; Type 0: Not a Combination Product		
2	NDC:51672-4117-9	473 mL in 1 BOTTLE; Type 0: Not a Combination Product	02/29/1988	
3	NDC:51672-4117-0	3785 mL in 1 BOTTLE; Type 0: Not a Combination Product	02/29/1988	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062876	02/29/1988	

Labeler - Taro Pharmaceuticals U.S.A., Inc. (145186370)

Establishment

Name	Address	ID/FEI	Business Operations
Taro Pharmaceutical Industries Ltd.		600072078	manufacture(51672-4117)

Revised: 12/2024 Taro Pharmaceuticals U.S.A., Inc.